证券代码：600201 证券简称：生物股份 公告编号：临 2025-040 金宇生物技术股份有限公司 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《关 于终止 2023 年度向特定对象发行 A 股股票并签署终止协议的公告》（公告编号： 临 2025-041）。 关联董事张翀宇先生、张竞女士作为发行对象，对本议案回避表决。 本议案已经公司第十二届董事会独立董事专门会议 2025 年第一次会议审议 通过。 特此公告。 金宇生物技术股份有限公司 董 事 会 第十二届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）第十二届董事会第二次会议 通知于 2025 年 7 月 9 日以电子邮件、书面形式发出，会议于 2025 年 7 月 14 日下 午 14：00 在公司会议室以现场和通讯表决相结合的方式召开,应参加表决的董事 召开程序符合《公司法》及《公司章程》的规定。会议由董事长张翀宇先生主持， 会议审议通过了如下议案： 审议并通过《关 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-041 金宇生物技术股份有限公司 关于终止2023年度向特定对象发行A股股票 并签署终止协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）于 2025 年 7 月 14 日召开第 十二届董事会第二次会议，审议通过了《关于终止向特定对象发行股票并签署相关 终止协议的议案》，同意公司终止 2023 年度向特定对象发行 A 股股票（以下简称 "本次发行"），并与内蒙古金宇生物控股有限公司（以下简称"生物控股"）、张翀 宇先生、张竞女士签署《附条件生效的股份认购协议之终止协议》 （以下简称"《终 止协议》"）。现将具体情况公告如下： 一、公司本次向特定对象发行股票的基本情况 公司分别于 2023 年 2 月 7 日、2023 年 3 月 16 日召开第十一届董事会第五次 会议、第十一届监事会第四次会议、2023 年第二次临时股东大会审议通过了《关 于公司 2023 年度向特定对象发行股票方案的议案》等议案，股东大会授 ...

证券代码：600201 证券简称：生物股份 公告编号：临2025-042 金宇生物技术股份有限公司 2025年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本期业绩预告适用情形：实现盈利，且净利润与上年同期相比下降 50%以 上。 金宇生物技术股份有限公司（以下简称"公司"）预计 2025 年半年度实现 归属于上市公司股东的净利润为 5,700 万元到 7,000 万元，与上年同期（法定披露 数据）相比，将减少 5,292 万元到 6,592 万元，同比减少 43.05%到 53.63%；预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的净利润为 3,000 万 元到 4,400 万元，与上年同期（法定披露数据）相比，将减少 6,386 万元到 7,786 万元，同比减少 59.21%到 72.19%。 一、本期业绩预告情况 （一）业绩预告期间 （三）本次业绩预告为公司根据经营情况的初步预测，未经会计师事务所审计。 二、上年同期经营业绩和财务状况 （一）2024 年半年度归属于 ...

生物股份（600201）公告，预计2025年半年度实现归属于上市公司股东的净利润为5700万元到7000万 元，与上年同期相比，将减少5292万元到6592万元，同比减少43.05%到53.63%。预计2025年半年度实 现归属于上市公司股东的扣除非经常性损益的净利润为3000万元到4400万元，与上年同期相比，将减少 6386万元到7786万元，同比减少59.21%到72.19%。 ...

Group 1 - The core index of the CSI 1000 major consumer index reported at 7845.59 points, with a decline of 4.42% over the past month and 2.47% over the past three months, while it has increased by 0.26% year-to-date [1] - The CSI 1000 index consists of 10 industry indices selected based on liquidity and market representation, providing diverse investment targets for investors [1] - The top ten holdings in the CSI 1000 major consumer index include: Lao Baigan Wine (4.28%), Lianhua Holdings (3.75%), Biological Shares (3.1%), Zhongchong Shares (3.01%), Shunxin Agriculture (2.86%), Yanjinpuzi (2.81%), Jinhui Industry (2.79%), Shanghai Jahwa (2.53%), Miaokelan Duo (2.52%), and Tangrenshen (2.43%) [1] Group 2 - The market share of the CSI 1000 major consumer index is divided between the Shanghai Stock Exchange (51.18%) and the Shenzhen Stock Exchange (48.82%) [1] - The industry composition of the CSI 1000 major consumer index includes: Food (36.45%), Breeding (25.12%), Alcohol (12.51%), Household Products (10.76%), Planting (8.80%), Beauty Care (4.35%), and Soft Drinks (2.01%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December, and can also be adjusted temporarily under special circumstances [2]

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., anticipates a significant increase in revenue for the first half of 2025, despite reporting a net loss attributed to various operational challenges [1][2]. Financial Performance Summary - Expected operating revenue for the period is projected to be approximately 105.81 million yuan, representing a year-on-year growth of 70.12% to 79.57% [1]. - The net loss attributable to shareholders is estimated to be between 9 million to 13 million yuan, compared to a loss of 11.06 million yuan in the same period last year, indicating a decrease of 17.56% to 18.61% [1]. - The net loss after deducting non-recurring gains and losses is expected to be between 10 million to 14 million yuan, a decline of 42.75% to 1.96% compared to a loss of 9.81 million yuan last year [1]. - Basic earnings per share are projected to be between -0.0126 yuan and -0.0087 yuan, compared to -0.0107 yuan per share in the previous year [1]. Reasons for Performance Changes - The primary reason for the company's losses is a slight decline in revenue from its subsidiary, Beijing Sihuan Biological Pharmaceutical Co., Ltd., along with increased management expenses due to legal fees related to a securities fraud case [2]. - Conversely, the increase in operating revenue is attributed to a strategic cooperation agreement between its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., and Jiangyin Xinganfa Trading Co., Ltd., leading to a substantial rise in sales of seedlings [2]. Other Relevant Information - The performance forecast is based on preliminary estimates from the company's finance department, with final figures to be confirmed in the official half-year report for 2025 [2].

Group 1 - Morning Light Biological expects a net profit of 202.0 million to 232.0 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1] - Northern Rare Earth anticipates a net profit of 900.0 million to 960.0 million yuan for the first half of 2025, with a significant year-on-year growth of 1882.54% to 2014.71% [1] - Youfa Group forecasts a net profit of 277.0 million to 307.0 million yuan for the first half of 2025, reflecting a year-on-year increase of 151.69% to 178.93% [1] Group 2 - Torch Electronics projects a net profit of approximately 247.0 million to 280.0 million yuan for the first half of 2025, indicating a year-on-year growth of 50.36% to 70.45% [3] - Zhiwei Intelligent expects a net profit of 91.98 million to 112.43 million yuan for the first half of 2025, with a year-on-year increase of 62.85% to 99.06% [4] - Youhao Group anticipates a net profit of 12.0 million yuan for the first half of 2025, representing a year-on-year growth of 51% [5] Group 3 - Nami Technology expects a net profit of 61.0 million to 73.0 million yuan for the first half of 2025, with a year-on-year increase of 35% to 62% [7] - Xinda Co. forecasts a net profit of 130.0 million to 150.0 million yuan for the first half of 2025, reflecting a substantial year-on-year growth of 2443.43% to 2834.73% [8] Group 4 - Shaanxi Coal Industry reported a coal production of 14.36 million tons in June, a year-on-year decrease of 5.07% [9] - Huanxu Electronics announced a consolidated revenue of 4.587 billion yuan in June, a year-on-year decline of 1.23% [10] Group 5 - Huadian International successfully issued 2.0 billion yuan in medium-term notes with a maturity of 3+N years and a coupon rate of 1.89% [20] - Zhongmin Energy reported a total power generation of 1.405 billion kilowatt-hours in the first half of 2025, a year-on-year decrease of 0.89% [20] Group 6 - Huaxia Biotech passed the FDA inspection with zero deficiencies, covering six major systems [21] - Ruikeda's application for convertible bond issuance has been accepted by the Shanghai Stock Exchange [22] Group 7 - Dafu Technology plans to invest no more than 100 million yuan in Anhui Yunta [42] - Tongda Co. won a bid for a project valued at 180.3 million yuan from the Southern Power Grid [46]

Market Overview - The Shanghai Composite Index fell by 0.13% on July 9, with 17 out of the 28 sectors rising, led by Media and Agriculture, Forestry, Animal Husbandry, and Fishery, which increased by 1.35% and 0.65% respectively [2] - The sectors with the largest declines were Non-ferrous Metals and Basic Chemicals, which dropped by 2.26% and 0.85% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.536 billion yuan, with only three sectors experiencing net inflows: Media (1.055 billion yuan), Retail (864 million yuan), and Construction Decoration (40.34 million yuan) [2] - The Electronic sector saw the largest net outflow, amounting to 7.789 billion yuan, followed by Non-ferrous Metals with 5.412 billion yuan [2] Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The Agriculture, Forestry, Animal Husbandry, and Fishery sector rose by 0.65% despite a net capital outflow of 437 million yuan [3] - Out of 103 stocks in this sector, 40 stocks increased, with one hitting the daily limit, while 55 stocks declined [3] - The top three stocks with net inflows were Xinwufeng (31.4665 million yuan), Haida Group (28.3706 million yuan), and Juxing Agriculture (21.9941 million yuan) [3][4] Top Gainers and Losers in Agriculture, Forestry, Animal Husbandry, and Fishery - **Top Gainers**: - Xinwufeng: +0.65%, 4.20% turnover, 31.4665 million yuan inflow [4] - Juxing Agriculture: +0.76%, 4.49% turnover, 21.9941 million yuan inflow [4] - **Top Losers**: - Muyuan Foods: -3.27%, 1.81% turnover, 71.5922 million yuan outflow [5] - Guolian Aquatic Products: -1.76%, 8.74% turnover, 45.2607 million yuan outflow [5]

证券代码：600201 证券简称：生物股份 公告编号：临 2025-038 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 7 月 11 日（周五） 16:00-18:00。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告。 金宇生物技术股份有限公司 董 事 会 二〇二五年七月十日 金宇生物技术股份有限公司 关于参加内蒙古辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，金宇生物技术股份有限公司（以下简 称 "公司"）将参加由内蒙古证监局、内蒙古自治区上市公司协会与深圳市全景网 络有限公司联合举办的"2025 年内蒙古辖区上市公司投资者集体接待日活 ...

关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司扬州优邦 生物药品有限公司（以下简称"扬州优邦"）及其他单位联合研制的鸡新城疫、禽 流感（H9 亚型）、禽腺病毒病（I 群，4 型）三联灭活疫苗（La Sota 株+WF 株+rHx 株）为新兽药，详情如下： 一、新兽药产品基本情况 新兽药名称：鸡新城疫、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）三 联灭活疫苗（La Sota 株+WF 株+rHx 株） 注册分类：三类 新兽药注册证书号：(2025)新兽药证字68号 研制单位：扬州优邦生物药品有限公司、苏州沃美生物有限公司、哈药集团 生物疫苗有限公司、肇庆大华农生物药品有限公司、四川农业大学 证券代码：600201 证券简称：生物股份 公告编号：临 2025-039 金宇生物技术股份有限公司 贮藏与有效期：2～8℃保存，有效期为 18 个月。 二、新兽药产品 ...